01—Abstract
Summary
Summary of the 8-K filed January 9, 2026. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. announced a CEO leadership transition on January 8, 2026.
James C. Foster, currently Chairman, President and Chief Executive Officer, intends to step down as CEO and Chairman of the Board, and Birgit Girshick, the Company's Chief Operating Officer, will become CEO, both effective May 5, 2026 (the "Transition Date"). Foster is expected to remain a non-executive director afterward, and Dr. Martin Mackay, the current Lead Independent Director, is expected to become Chair of the Board on the Transition Date.
Girshick has also been nominated to join the Board at the 2026 Annual Meeting of Shareholders, expected on the Transition Date, and the Board approved increasing its size from 11 to 12 seats effective then. Elliott Investment Management L.P. and related Elliott entities provided limited consents under their May 6, 2025 Cooperation Agreement with the Company to permit this addition. Compensation terms for Girshick include a base salary increase to $1,200,000a effective February 1, 2026, a target annual cash incentive of 100% of base salary effective May 1, 2026, and an initial equity grant with a target fair market value of $9,000,000 (80% performance share units, 20% restricted stock units) expected in May 2026.
Her change-in-control agreement is to be amended before the Transition Date, providing a lump sum severance of three times base salary plus target bonus, three years of benefits continuation, and outplacement services upon a qualifying termination within the first year after a change in control. Foster received a grant of restricted stock units with an underlying fair market value of $3,000,000,b expected on March 2, 2026, with two-year cliff vesting.
02—Key points
Key Highlights
- James C. Foster will step down as Chief Executive Officer and Chairman of the Board, effective May 5, 2026, and is expected to remain a non-executive director.
- Birgit Girshick, the Company's Chief Operating Officer, will be appointed Chief Executive Officer effective May 5, 2026, and has been nominated to the Board at the 2026 Annual Meeting.
- Dr. Martin Mackay, current Lead Independent Director, is expected to become Chair of the Board effective on the Transition Date.
- The Board approved increasing its size from 11 to 12 directors, effective on the Transition Date, with Elliott entities providing consents under their May 6, 2025 Cooperation Agreement.
- Girshick's base salary will increase to $1,200,000 effective February 1, 2026, with her target annual cash incentive rising to 100% of base salary effective May 1, 2026.
- Girshick's initial equity grant has a target fair market value of $9,000,000, split 80% performance share units and 20% restricted stock units, expected in May 2026.
- Foster will receive restricted stock units with an underlying fair market value of $3,000,000, expected March 2, 2026, with two-year cliff vesting, in recognition of his service as CEO for part of fiscal 2026.
03—Questions
Frequently Asked Questions
When will the CEO transition take effect?
The transition is effective as of May 5, 2026, the Transition Date, when Girshick becomes CEO and Foster steps down as CEO and Chairman.
Who will lead the Board after the transition?
Dr. Martin Mackay, the current Lead Independent Director, is expected to become Chair of the Board effective on the Transition Date.
What compensation will the new CEO receive?
Girshick's base salary increases to $1,200,000 effective February 1, 2026, her target annual cash incentive becomes 100% of base salary effective May 1, 2026, and she receives an initial equity grant with a target fair market value of $9,000,000 (80% performance share units, 20% restricted stock units), expected in May 2026.
What severance protection does the new CEO have?
Under an amended and restated Change in Control Agreement the Company intends to enter before the Transition Date, a termination without cause or for good reason within the first year after a change in control would entitle Girshick to a lump sum equal to three times her base salary plus target bonus, three years of group medical benefits and perquisites continuation, and outplacement services.
What is Foster receiving in connection with his departure as CEO?
Foster received approval for a grant of restricted stock units with an underlying fair market value of $3,000,000, expected on March 2, 2026, with cliff vesting over two years. After the next annual shareholder meeting, he is expected to receive the same compensation as other non-executive directors.
04—Continue